Positron emission tomography in acromegaly and other pituitary adenoma patients

Neuroendocrinology

Volumn 83, Issue 3-4, 2006, Pages 205-210

  Muhr, Carin ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C methionine; 18F fluorodeoxyglucose; Acromegaly; Deprenyl; Dopamine D2 receptors; Intracranial tumor; Pituitary adenoma; Positron emission tomography

Indexed keywords

3 METHYLSPIPERONE C 11; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CABERGOLINE; CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; METHIONINE C 11; PERGOLIDE; QUINAGOLIDE; RACLOPRIDE C 11; SELEGILINE; SELEGILINE C 11; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; ADENOMA; CONFERENCE PAPER; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EPITOPE MAPPING; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; METABOLISM; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR BINDING; SKULL BASE TUMOR;

ACROMEGALY; ADENOMA; BRAIN MAPPING; DOPAMINE ANTAGONISTS; HUMANS; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2;

EID: 33750035803     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095529     Document Type: Conference Paper

References (26)

1. Muhr C, Bergström M: Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest 1991;14:509-528.
2. Bergstrom M, Muhr C, Lundberg PO, Bergstrom K, Gee AD, Fasth KJ, Langstrom B: Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 1987;11:815-819.
3. Muhr C, Bergstrom M, Lundberg PO, Hartman M, Bergstrom K, Pellettieri L, Langstrom B: Malignant prolactinoma with multiple intracranial metastases studied with positron emission tomography. Neurosurgery 1988;22:374-379.
4. 11C-N-methylspiperone. J Comput Assist Tomogr 1986;10:175-180.
5. 11C-L-deprenyl. Neurosurgery 1992;30:855-861.
6. Nyberg G, Bergstrom M, Enblad P, Lilja A, Muhr C, Langstrom B: PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol 1997;117:482-489.
7. 11C-methionine. J Comput Assist Tomogr 1987;11:384-389.
8. Muhr C: Positron emission tomography in sellar tumors - in vivo metabolic, receptor, and enzyme characterization; in Thapar K, Scheitauer BW, Lloyd RV (eds): Diagnosis and Management of Pituitary Adenomas. Totowa, Humana Press, 2000, vol 12, pp 219-224.
9. 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. Eur J Nucl Med 1991;18:453-460.
10. De Souza B, Brunetti A, Fulham MJ, Brooks RA, DeMichele D, Cook P, Nieman L, Doppman JL, Oldfield EH, Di Chiro G: Pituitary microadenomas: a PET study. Radiology 1990;177:39-44.
11. 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 2006;33:169-178.
12. Levivier M, Wikler D Jr, Massager N, David P, Devriendt D, Lorenzoni J, Pirotte B, Desmedt F, Simon S Jr, Goldman S, Van Houtte P, Brotchi J: The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 2002;97:542-550.
13. De Landsheere C, Lamotte D: Methods and clinical applications of positron emission tomography in endocrinology. Ann Endocrinol (Paris) 1990;51:148-154.
14. Campeau RJ, David O, Dowling AM: Pituitary adenoma detected on FDG positron emission tomography in a patient with mucosa-associated lymphoid tissue lymphoma. Clin Nucl Med 2003;28:296-298.
15. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E: Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004;48:150-163.
16. Komori T, Martin WH, Graber AL, Delbeke D: Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature. Clin Nucl Med 2002;27:176-178.
17. Koo CW, Bhargava P, Rajagopalan V, Ghesani M, Sims-Childs H, Kagetsu NJ: Incidental detection of clinically occult pituitary adenoma on whole-body FDG PET imaging. Clin Nucl Med 2006;31:42-43.
18. Levivier M, Massager N, Wikler D, Goldman S: Modern multimodal neuroimaging for radiosurgery: the example of PET scan integration. Acta Neurochir Suppl 2004;91:1-7.
19. Muhr C: Positron emission tomography (PET) in pituitary adenomas; in Landolt AM, Reilly PL, Vance ML (eds): Pituitary Adenomas. New York, Churchill Livingstone, Medical Division of Longman Group UK Ltd, 1996, pp 229-238.
20. 18F-fluoro-ethyl-spiperone. Eur J Nucl Med 1997;24:1149-1155.
21. Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM, Ramirez A, Ortega S, Sabatel G, Ramos C, de la Riva-Aguilar A: The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 2005;78:110-115.
22. De Herder WW, Lamberts SW: Imaging of pituitary tumours. Baillieres Clin Endocrinol Metab 1995;9:367-389.
23. 2 receptor radioligand. Clin Endocrinol (Oxf) 1996;45:755-767.
24. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998;83:248-252.
25. 123I-methoxybenzamide. Clin Endocrinol (Oxf) 2000;52:437-445.
26. 2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. Eur J Nucl Med 1999;26:46-50.